Quoin Pharmaceuticals, Ltd. — Director's Dealing 2026

Feb 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2026-02-04

Reporting Person: Culverwell Anthony James (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-04	Share Option (Right to Buy)	$7.37	A	21709	Acquired	2036-02-04	ADS (21709)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.